A 1982 paper published in Nature introduced the concept of inverse agonism, fundamentally shifting the academic understanding of benzodiazepine receptors. This research milestone was achieved by David John Nutt, who has spent decades investigating the complex relationship between pharmacology and the brain. His work spans the clinical, institutional, and policy landscapes of modern neuropsychopharmacology.
Academic Foundation
Nutt attended Bristol Grammar School before enrolling at Downing College, Cambridge, where he earned his medical degree in 1972. He completed clinical training at Guy's Hospital in 1975. His early scientific career involved research at the Radcliffe Infirmary between 1978 and 1982, focusing on the GABA ionophore complex. Following this, he held lecturing roles at the University of Oxford and served as a Fogarty visiting scientist in Bethesda, Maryland, before joining the University of Bristol in 1988.
Twenty questions, eight minutes on the clock, and a percentile measured against everyone who has taken it. No sign-up.
Take the IQ test →Institutional Leadership
In 2009, Nutt joined Imperial College London, where he took the Edmond J Safra chair in Neuropsychopharmacology. He currently directs the Neuropsychopharmacology Unit and serves as deputy head of the Centre for Psychedelic Research. His administrative influence extends globally, having presided over the European College of Neuropsychopharmacology and the European Brain Council. He also maintains an editorial role for the Journal of Psychopharmacology.
Drug Policy and Controversy
Nutt chaired the Advisory Council on the Misuse of Drugs until 2009. His tenure was marked by public friction with government officials regarding drug classification. A notable point of contention was a 2009 editorial comparing the risks of horse riding with those of ecstasy, which he termed 'equasy.' Following his departure from the council, he founded Drug Science, an organization dedicated to providing independent data on drug harms, including his influential 2010 multi-criteria analysis.
Commercial Ventures
Nutt expanded his research into the private sector by co-founding GABAlabs in 2019. The venture seeks to market alcohol alternatives that interact with GABA receptors without the health risks associated with ethanol. In 2021, the company launched Sentia, a plant-based beverage designed to mimic social effects linked to alcohol consumption. These projects reflect his ongoing interest in the psychopharmacology of recreational substances.
Fast facts
- Born: 1951
- Education: Downing College, Cambridge
- Current position: Edmond J Safra chair, Imperial College London
- Notable honor: John Maddox Prize (2013)
- Professional society: Fellow of the Academy of Medical Sciences (2002)
- Primary research focus: Neuropsychopharmacology
Questions readers ask
What is the primary focus of the organisation Drug Science?
It provides independent, evidence-based information regarding the harm and policy associated with drugs.
What are the goals of the company GABAlabs?
The company researches and markets alcohol alternatives designed to provide social effects while reducing health risks.
Achievements
- John Maddox Prize — 2013
- Held posts at Imperial College London, University of Bristol and University of Cambridge
- Fields: neuropsychopharmacology and narcology
